Ongoing studies for the primary prevention of cancer-associated VTE in adult patients
| Study . | Study design . | Intervention . | Status . |
|---|---|---|---|
| Prophylaxis of Venous Thromboembolism in Advanced Lung Cancer (PROVE; NCT03090880) | RCT | Tinzaparin 4500 U vs usual care | Recruiting |
| Apixaban for Primary Prevention of Venous Thromboembolism in Patients with Multiple Myeloma (NCT02958969) | RCT | Apixaban 2.5 mg twice daily vs placebo | Active, not recruiting |
| ASA Vs Rivaroxaban in Newly Diagnosed or Relapsed and Refractory Multiple Myeloma Patients Treated with Len-Dex Combination Therapy (RithMM; NCT03428373) | RCT | Rivaroxaban 10 mg daily vs aspirin 81 mg daily | Not yet recruiting |
| Study . | Study design . | Intervention . | Status . |
|---|---|---|---|
| Prophylaxis of Venous Thromboembolism in Advanced Lung Cancer (PROVE; NCT03090880) | RCT | Tinzaparin 4500 U vs usual care | Recruiting |
| Apixaban for Primary Prevention of Venous Thromboembolism in Patients with Multiple Myeloma (NCT02958969) | RCT | Apixaban 2.5 mg twice daily vs placebo | Active, not recruiting |
| ASA Vs Rivaroxaban in Newly Diagnosed or Relapsed and Refractory Multiple Myeloma Patients Treated with Len-Dex Combination Therapy (RithMM; NCT03428373) | RCT | Rivaroxaban 10 mg daily vs aspirin 81 mg daily | Not yet recruiting |